^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-L1 negative + TMB-L + STING overexpression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule, TMB | Tumor Mutational Burden, STING, STING1, Stimulator Of Interferon Response CGAMP Interactor,Transmembrane Protein 173, Endoplasmic Reticulum Interferon Stimulator, Stimulator Of Interferon Genes Protein, Endoplasmic Reticulum IFN Stimulator, TMEM173, ERIS, N-Terminal Methionine-Proline-Tyrosine-Serine Plasma Membrane Tetraspanner, Mitochondrial Mediator Of IRF3 Activation, Stimulator Of Interferon Protein, Stimulator Of Interferon Genes, Mediator Of IRF3 Activation, STING-Beta
    Entrez ID:
    29126; 340061
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over1year
    Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). (ASCO 2023)
    To our knowledge this is the largest real-world dataset indicating that enrichment of both the STING gene, and gene signatures associated with the STING pathway represent valuable transcriptomic biomarkers to stratify pts with PDL1-negative and TMB-Low NSCLC who benefit more from IO therapies. Conversely, novel IO combination strategies need to be employed in STING-low tumors to enhance outcomes. >
    Checkpoint inhibition • Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • STING (stimulator of interferon response cGAMP interactor 1) • CD80 (CD80 Molecule)
    |
    TP53 mutation • STK11 mutation • PD-L1 negative • TMB-L • PD-L1 negative + TMB-L • PD-L1 negative + TMB-L + STING overexpression
    |
    PD-L1 IHC 22C3 pharmDx • MI Tumor Seek™